Algernon Pharmaceuticals announces first site for U.S. clinical trial for Ifenprodil

Algernon Pharmaceuticals announces first site for U.S. clinical trial for Ifenprodil

 

 

Algernon Pharmaceuticals (CSE: AGN-OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive Vancouver with news the company has announced a site for their multinational Phase 2b/3 human study of Ifenprodil for COVID-19.

Moreau says that study will be conducted at the Westchester Research Center at Westchester General Hospital in Miami, Florida. The lead researcher will be Dr. Aimee Gonzalez.

Share via
Copy link
Powered by Social Snap